In a report released today, Salim Syed from Mizuho Securities maintained a Buy rating on Vaxcyte (PCVX – Research Report). The company’s shares closed last Friday at $69.46. Discover the ...

BofA lowered the firm’s price target on Vaxcyte (PCVX) to $137 from $157 following the company’s report of Phase 2 dose-finding data for VAX-24 in infants, but thinks the reaction that saw the ...

For people with low visibility, a magnifying glass isn’t effective enough. You need an extra lighting feature to improve their visibility. Moreover, a good lighting system is also useful to illuminate ...